HITIQ (ASX:HIQ) has announced its receipt of an approval from the US patent office protecting its concussion management IP.
The company is a unique one on the ASX; it provides software and hardware designed to monitor concussive impacts in the brain incurred by sports players. This is done through scans which are backed by a mouthguard product containing inbuilt sensors.
It is this product, Nexus, now the subject of a patent in the US IP system.
“Receiving approval for our maiden US patent signals our technology as globally relevant and helps forge a pathway into the US, our key commercial jurisdiction,” HITIQ CEO Mike Vegar said.
“This approval ensures our ability to protect an integral component of our product and technology in the largest addressable market within our product category.
“We will continue to build our global patent portfolio with our pipeline of IP activity to gradually emerge.”
HIQ last traded at 1.6cps.